Lv1
30 积分 2025-07-16 加入
An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma
1天前
待确认
Interstitial lung disease biomarkers: a systematic review and meta-analysis
8天前
已完结
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
9天前
已完结
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
1个月前
已完结
EGFR as a Potential Target for the Treatment of Pancreatic Cancer: Dilemma and Controversies
2个月前
已完结
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
2个月前
已完结
IL-6 Blockade in Cytokine Storm Syndromes
3个月前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
3个月前
已完结
Dual-payload Antibody–drug Conjugates: Taking a Dual Shot
4个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
4个月前
已完结
皖公网安备34019202002308
